Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

Journal of Virology

Volumn 74, Issue 12, 2000, Pages 5477-5485

  Guirakhoo, F ^a   Weltzin, R ^a   Chambers, T J ^b   Zhang, Z X ^a   Soike, K ^c   Ratterree, M ^c   Arroyo, J ^a   Georgakopoulos, K ^a   Catalan, J ^a   Monath, T P ^a  

^a Acambis   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX D2; DENGUE VACCINE; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG ANTIGENICITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY; VACCINE PRODUCTION; VIRUS RECOMBINANT; YELLOW FEVER FLAVIVIRUS;

AMINO ACID SUBSTITUTION; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; CELL LINE; DENGUE; DENGUE VIRUS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENES, VIRAL; MACACA MULATTA; MICE; NEUTRALIZATION TESTS; SERIAL PASSAGE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES; VIREMIA; VIRULENCE; VIRUS REPLICATION; YELLOW FEVER VIRUS;

EID: 0034119311     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.12.5477-5485.2000     Document Type: Article

References (32)

1. Brandt, W. E., R. D. Cardiff, and P. K. Russell. 1970. Dengue virions and antigens in brain and serum of infected mice. J. Virol. 6:500-506.
2. Bray, M., R. Men, I. Tokimatso, and C. J. Lai. 1998. Genetic determinant responsible for acquisition of dengue type 2 virus mouse neurovirulence. J. Virol. 72:1647-1651.
3. Calisher, C., N. Karabatsos, J. M. Dalrymple, R. E. Shope, J. S. Porterfield, E. G. Westaway, and W. E. Brandt. 1989. Antigenic relationships among flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol. 70:37-43.
4. Chambers, T. J., A. Nestorowicz, P. W. Mason, K. H. Eckels, and C. M. Rice. 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
5. Deubel. V., R. M. Kinney, and D. W. Trent. 1988. Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue-2 virus, Jamaica: comparative analysis of the full-length genome. Virology 165:234-244.
6. Eckels, K. H., W. E. Brandt, V. R. Harrison, J. M. McCoun, and P. K. Russell. 1976. Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect. Immun. 14:1221-1227.
7. Gruenberg, A., W. S. Woo, A. Biedrzycka, and P. J. Wright. 1988. Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, New Guinea C and PUO-218 strains. J. Gen. Virol. 69:1391-1398.
8. Gualano, R. C., M. J. Pryor, M. R. Cauchi, P. J. Wright, and A. D. Davidson. 1998. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol. 79:437-446.
9. Guirakhoo, F., Z. X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. T. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
10. Hahn, Y. S., R. Galler, T. Huhnkapiller, J. M. Dalrymple, J. H. Strauss, and E. G. Strauss. 1988. Nucleotide sequence of dengue-2 RNA and comparison of the encoded proteins with those of other flaviviruses. Virology 162:167-180.
11. Halstead, S. B. 1988. Pathogenesis of dengue: challenge to molecular biology. Science 239:476-481.
12. Halstead, S. B. 1989. Antibody, macrophage, dengue virus infection, shock and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis. 11:S830-S839.
13. Harrison, V. R., K. H. Eckels, J. W. Sagartz, and P. K. Russell. 1977. Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infect. Immun. 18:151-156.
14. Lai, C. J., M. Bray, R. Men, A. Cahour, W. Chen, H. Kawano, M. Tadano, K. Hiramatsu, I. Tokimatsu, A. Pletnev, S. Arakai, G. Shameem, M. Rinaudo. 1998. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Virol. 10:173-179.
15. Mason, P. W., P. C. McAda, T. L. Mason, and M. J. Fournier. 1987. Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1. Virology 161: 262-267.
16. Monath, T. P. 1994. Dengue-the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91:2395-2400.
17. Monath, T. P. 1999. Yellow fever, p. 815-879. In S. Plotkin and W. Orenstein (ed.), Vaccines, W. B. Saunders and Company, Philadelphia, Pa.
18. Monath, T. P., I. Levenbook, K. Soike, Z. X. Zhang, M. Ratterree, K. Draper, A. D. T. Barrett, R. Nichols, R. Weltzin, J. Arroyo, and F. Guirakhoo. 2000. Chimeric yellow fever 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74:1742-1751.
19. Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. T. Barrett, R. E. Shope, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) and the capsid and nonstructural genes of yellow fever (17D) is safe, immunogenic and protective in non-human primates. Vaccine 17:1869-1882.
20. National Institutes of Health. 1998. Guide for the care and use of laboratory animals, rev. ed. Department of Health and Human Services publication no. (NIH) 85-23. National Institutes of Health, Bethesda, Md.
21. Putnak, R., D. A. Barvir, J. M. Burrous, D. R. Dubois, V. M. D'Andrea, C. H. Hoke, J. C. Sadoff, and K. H. Eckels. 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174:1176-1184.
22. Rice, C. M., A. Grakoui, R. Galler, and T. J. Chambers. 1989. Transcription of infectious yellow fever virus RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
23. Rice, C. M., E. M. Lenches, S. R. Eddy, S. J. Shin, R. L. Sheets, and J. H. Strauss. 1985. Nucleotide sequence of yellow fever virus: implication for flavivirus gene expression and evolution. Science 229:726-733.
24. Rosen, L. 1958. Experimental studies of New World monkeys with dengue and yellow fever. Am. J. Trop. Med. Hyg. 7:406-410.
25. Russell, P. K., and A. Nisalak. 1967. Dengue virus identification by the plaque reduction neutralization test. J. Immunol. 99:291-296.
26. Sabin, A. B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
27. Sabin, A. B., and R. W. Schlesinger. 1945. Production of immunity to dengue with virus modified by propagation in mice. Science 101:640-642.
28. Scott, R. M., K. H. Eckels, W. H. Bancroft, P. L. Summers, J. M. McCown, J. H. Anderson, and P. K. Russell. 1983. Dengue-2 vaccine: dose response in volunteers in relation to yellow fever immune status. J. Infect. Dis. 148:1055-1060.
29. Simmons, J. S., J. H. St. John, and F. H. Reynolds. 1931. Experimental studies of dengue. Philipp. J. Sci. 44:1-251.
30. Sumiyoshi, H., G. H. Tignor, and R. E. Shope. 1995. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171:144-151.
31. Whitehead, R. H., V. Chaicumpa, L. C. Olson, and P. K. Russell. 1970. Sequential dengue virus infections in the white-handed gibbon (Hylobates lar). Am. J. Trop. Med. Hyg. 19:94-102.
32. Wisseman, C. L., Jr., B. H. Sweet, E. C. Rosenzweig, and O. R. Eylar. 1963. Attenuated living type 1 dengue vaccines. Am. J. Trop. Med. Hyg. 12:620-623.